Stryker Orthopaedics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Stryker Orthopaedics sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).
Stryker Orthopaedics: 27 sponsored US clinical trials, 1 recruiting.
Stryker Orthopaedics sponsors 27 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 10 completed. The most-studied condition in this pipeline is Replacement, with 2 trials.
Top-decile sponsor footprint
Stryker Orthopaedics ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (47.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
27 total, page 1 of 1
Restoration Anatomic Acetabular Shell Revision Study
NCT05591859
Insignia™ Hip Stem Outcomes Study
NCT05144191
Triathlon All-Polyethylene Tibia Outcomes Study
NCT04636190
Trident II Tritanium Acetabular Shell Outcomes Study
NCT02999009
Triathlon Tritanium Cone Augments Outcomes Study
NCT02521103
Mako-MORE Registry
NCT07647354
Triathlon PSR Outcomes Study
NCT04618770
Trident II Revision Outcomes Study
NCT04317586
Triathlon Tritanium Knee Outcomes Study
NCT02155712
Secur-Fit Advanced Outcomes Study
NCT01917929
Tritanium® Primary Acetabular Shell Study
NCT01063751
Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study
NCT01420237
Pelvic Alignment Level (PAL) Instrument Evaluation
NCT01312428
Rejuvenate Modular Outcomes Study
NCT01257568
A Prospective, Post-market, Multi-center Feasibility Study of the BioDuct® Meniscal Repair Device
NCT01270919
Triathlon® Partial Knee Replacement (PKR) Outcomes Study
NCT00966979
Triathlon Total Stabilizer (TS) Outcomes Study
NCT00958789
LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study
NCT00510458
Trident® Tritanium™ Acetabular Shell Revision Study
NCT00535626
Accolade® TMZF® Hip Stem Outcomes Study
NCT00957658
Triathlon® Posteriorly Stabilized (PS) Total Knee System - Outcomes Study
NCT00957021
Trident® X3 Polyethylene Insert Study
NCT00958191
Triathlon® Cruciate Retaining (CR) Total Knee System Outcomes Study
NCT00957723
Restoration® Modular Revision Hip System Post Market Study
NCT00962013
ABC/Trident® Ceramic Post Approval Study
NCT00960206
Scorpio® Cruciate Retaining (CR) Outcomes Study
NCT00965146
Omnifit Hydroxylapatite (HA) Hip Outcomes Study
NCT00958347
What is open in the Stryker Orthopaedics pipeline
1 recruiting of 27 indexed (4% open); 10 completed (37%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Replacement (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Stryker Orthopaedics: open-pipeline peers nationwide
Peers matched on 27 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Stryker Orthopaedics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 27 trials (± recruiting share)
- Akron Children's Hospital · 27 trials · 7% recruiting
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 27 trials · 0% recruiting
- AVEO Pharmaceuticals · 27 trials · 7% recruiting
- Dompé Farmaceutici S.p.A · 27 trials · 15% recruiting
Sponsors near 4% open enrollment (± trial volume)
- US Oncology Research · 4% recruiting · 27 trials
- GlaxoSmithKline · 4% recruiting · 1,345 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
What to do with this Stryker Orthopaedics page
27 registered trials is a research-attention snapshot, not an endorsement of Stryker Orthopaedics or any single study.
- 1 of Stryker Orthopaedics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Replacement is the condition Stryker Orthopaedics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Replacement trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Stryker Orthopaedics pipeline card: 27 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.